Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an announcement.
Paradigm Biopharmaceuticals has announced the date for its upcoming Annual General Meeting (AGM), scheduled for November 19, 2025. The company also informed stakeholders about the closing date for director nominations, which is set for September 29, 2025. This announcement is significant as it outlines the timeline for key governance activities, which could impact the company’s strategic direction and stakeholder engagement.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is a company in the pharmaceutical industry, focusing on the development and commercialization of therapies for unmet medical needs. It operates primarily in the biopharmaceutical sector, aiming to address specific health conditions with innovative treatments.
YTD Price Performance: -21.33%
Average Trading Volume: 869,046
Technical Sentiment Signal: Sell
Current Market Cap: A$121.5M
Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.